Comments on: HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

Comments on: HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session https://9krapalm.com/harmoni-6-demonstrates-significant-overall-survival-benefit-hr0-66-ivonescimab-plus-chemotherapy-superior-to-pd-1-plus-chemotherapy-in-first-line-sq-nsclc-landmark-results-to-be-presented-at-asco/ เสิร์ฟข่าวไอที อัปเดตเทคโนโลยีสไตล์ @krapalm Sun, 31 May 2026 13:47:58 +0000 hourly 1 https://wordpress.org/?v=7.0.2